CN109310752B - 提供一系列减毒表型的在m2-2 orf中具有突变的重组呼吸道合胞病毒株 - Google Patents

提供一系列减毒表型的在m2-2 orf中具有突变的重组呼吸道合胞病毒株 Download PDF

Info

Publication number
CN109310752B
CN109310752B CN201680081646.4A CN201680081646A CN109310752B CN 109310752 B CN109310752 B CN 109310752B CN 201680081646 A CN201680081646 A CN 201680081646A CN 109310752 B CN109310752 B CN 109310752B
Authority
CN
China
Prior art keywords
rsv
seq
protein
recombinant
recombinant rsv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680081646.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN109310752A (zh
Inventor
P·L·柯林斯
U·J·巴克霍尔兹
C·罗格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Publication of CN109310752A publication Critical patent/CN109310752A/zh
Application granted granted Critical
Publication of CN109310752B publication Critical patent/CN109310752B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201680081646.4A 2015-12-11 2016-12-12 提供一系列减毒表型的在m2-2 orf中具有突变的重组呼吸道合胞病毒株 Active CN109310752B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562266199P 2015-12-11 2015-12-11
US62/266,199 2015-12-11
PCT/US2016/066146 WO2017100759A1 (en) 2015-12-11 2016-12-12 Recombinant respiratory syncytial virus strains with mutations in the m2-2 orf providing a range of attenuation phenotypes

Publications (2)

Publication Number Publication Date
CN109310752A CN109310752A (zh) 2019-02-05
CN109310752B true CN109310752B (zh) 2022-12-16

Family

ID=57714677

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680081646.4A Active CN109310752B (zh) 2015-12-11 2016-12-12 提供一系列减毒表型的在m2-2 orf中具有突变的重组呼吸道合胞病毒株

Country Status (9)

Country Link
US (2) US10655109B2 (cg-RX-API-DMAC10.html)
EP (1) EP3386539A1 (cg-RX-API-DMAC10.html)
JP (2) JP7079197B2 (cg-RX-API-DMAC10.html)
KR (2) KR102854980B1 (cg-RX-API-DMAC10.html)
CN (1) CN109310752B (cg-RX-API-DMAC10.html)
AR (1) AR106956A1 (cg-RX-API-DMAC10.html)
AU (1) AU2016366771B2 (cg-RX-API-DMAC10.html)
CA (1) CA3007408A1 (cg-RX-API-DMAC10.html)
WO (1) WO2017100759A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3630173A1 (en) * 2017-05-29 2020-04-08 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant chimeric bovine/human parainfluenza virus 3 expressing rsv g and its use
US20230279362A1 (en) * 2020-06-05 2023-09-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Live attenuated respiratory syncytial virus
AU2024380679A1 (en) 2023-11-17 2026-07-02 Sanofi Vaccines US Inc. Trehalose vaccine formulation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224404A1 (de) 1982-06-30 1984-01-05 LuK Lamellen und Kupplungsbau GmbH, 7580 Bühl Reibungskupplung sowie verfahren zu deren montage
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
US6713066B1 (en) 1996-07-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US20040005542A1 (en) * 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
WO2002044334A2 (en) * 2000-11-28 2002-06-06 Aviron, Inc. Recombinant rsv virus expression systems and vaccines
DE10118446A1 (de) * 2001-04-12 2002-10-17 Thomas Hartung Prüfverfahren zur Untersuchung fließfähiger Medien auf Gehalte an mikrobiellen Toxinen
PL3511015T3 (pl) 2012-04-13 2021-09-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetycznie stabilna żywa atenuowana szczepionka przeciw syncytialnemu wirusowi oddechowemu i jej wytwarzanie
WO2015041924A2 (en) * 2013-09-18 2015-03-26 Medimmune, Llc Recombinant respiratory syncytial virus (rsv) and caccines
US10947512B2 (en) 2015-08-14 2021-03-16 Research Institute At Nationwide Children's Hospital Respiratory syncytial virus having altered NS1 protein function and related materials and methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells;BUKREYEV A 等;《JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY》;20011201;第75卷(第24期);12128-12140 *
Respiratory Syncytial Virus That Lacks Open Reading Frame 2 of the M2 Gene (M2-2) Has Altered Growth Characteristics and Is Attenuated in Rodents;HONG JIN等;《JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY》;20000101;第79卷(第1期);74-82 *
The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription;BERMINGHAM ALISON等;《PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, NATIONAL ACADEMY OF SCIENCES》;19990928;第96卷(第20期);11259–11264 *

Also Published As

Publication number Publication date
RU2018125246A3 (cg-RX-API-DMAC10.html) 2020-05-25
BR112018011674A2 (pt) 2018-12-04
US20190040365A1 (en) 2019-02-07
US11332721B2 (en) 2022-05-17
AR106956A1 (es) 2018-03-07
KR102854980B1 (ko) 2025-09-03
JP2018536428A (ja) 2018-12-13
JP7079197B2 (ja) 2022-06-01
US20200283740A1 (en) 2020-09-10
CN109310752A (zh) 2019-02-05
JP7357709B2 (ja) 2023-10-06
RU2018125246A (ru) 2020-01-15
KR20180085803A (ko) 2018-07-27
KR20250134719A (ko) 2025-09-11
CA3007408A1 (en) 2017-06-15
WO2017100759A1 (en) 2017-06-15
AU2016366771B2 (en) 2022-04-07
EP3386539A1 (en) 2018-10-17
AU2016366771A1 (en) 2018-07-12
JP2022088376A (ja) 2022-06-14
US10655109B2 (en) 2020-05-19

Similar Documents

Publication Publication Date Title
CN101012454B (zh) 从克隆的核苷酸序列制备减毒呼吸道合胞病毒疫苗的方法
AU2021218112B2 (en) Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
AU2020203460B2 (en) Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
US6689367B1 (en) Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
CN113322264B (zh) 具有沉默突变的重组rsv、其相关疫苗和方法
KR20110063863A (ko) 생 약독화 호흡기 세포융합 바이러스
KR100746979B1 (ko) 클로닝된 뉴클레오티드 서열로부터의 약독화된 키메릭호흡기 신시티움 바이러스 백신의 제조
JP7357709B2 (ja) さまざまな弱毒化表現型をもたらすｍ２－２ ｏｒｆにおける突然変異を含む組換えｒｓウイルス株
KR20210005090A (ko) 키메라 벡터
CN108699535B (zh) 包含ns1和ns2基因迁移的重组呼吸道合胞病毒株
KR20230021115A (ko) 생 약독화된 호흡기 세포융합 바이러스 (live attenuated respiratory syncytial virus)
KR20230038205A (ko) 키메라 rsv 및 코로나바이러스 단백질, 면역원성 조성물, 및 사용 방법
RU2773746C2 (ru) Рекомбинантные штаммы респираторно-синцитиального вируса с мутациями в м2-2 orf, обеспечивающими диапазон аттенуирующих фенотипов
BR112018011674B1 (pt) Vírus sincicial respitatório (rsv) recombinante, seu método de produção, seus usos, bem como molécula de polinucleotídeo isolada, vetor e composição farmacêutica
AU5591601A (en) Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20370419

TG01 Patent term adjustment